ANTITUMOUR POTENTIAL OF PASSIFLORA INCARNATA L AGAINST EHRLICH ASCITES CARCINOMA

NAGINENI SUJANA*, SANTHANALAXSHMI RAMANATHAN*, VENKETEla VIMALA*, MEENAKSHI SUNDARAM MUTHURAMAN*, BRINDHA PEMAIH*  
*Department of Biotechnology, School of Chemical & Biotechnology, *CARISM, SASTRA University, Thirumalaisamudram, Thanjavur – 613401, Tamil Nadu, India.

Received: 16 March 2012, Revised and Accepted: 20 April 2012

ABSTRACT
The present investigation aims at to evaluate the anti-tumour potential of the ethanolic extract of Passiflora incarnata L (EEPI) on Ehrlich ascites carcinoma (EAC). Ethanol extract of Passiflora incarnata L was subjected to preliminary phytochemical screening and the antitumor effect of EEPI was assessed by employing in-vitro methods. Compounds present in the plant extract were identified using GC-MS and attempts were made to understand the mechanism of action using in silico methods. Present study revealed that Passiflora incarnata (EEPI) possessed significant antitumor activity against EAC.

Keywords: Passiflora incarnata L, Ehrlich ascites carcinoma, In-vitro, In silico.

INTRODUCTION
Worldwide about 20 million people per year are diagnosed with cancer and more than 6 million mortalities are recorded and rate of cancer incidences increases every year. The statistics released by the American Cancer Society in 2006 reveals that the total number of deaths due to cancer in 2005 was 7.6 million. By 2050, over 20 million new cancer cases and over 17 million cancer deaths are probable to occur in the world (1). Ever since man existed, he had survived and prevented several diseases including cancer by using traditional herbs. Till date large number of herbal products has been screened for their anticancer potential through various experimental models. This has caused the discovery of the several drugs by the pharmaceutical and scientific communities. This prompted us to evaluate the antitumor activity of a common plant in hills and plain botanically equated as Passiflora incarnata.

MATERIALS AND METHODS

Plant material
The leaves of Passiflora incarnata L were obtained from in and around Ooty and the collected plant material was identified and authenticated by CARISM department, SASTRA University, Thanjavur.

Preparation of leaf powder
Leaves of Passiflora incarnata L were collected and dried under shade. The dried materials were mechanically powdered after keeping them at room temperature for 48 hours. These coarse powder materials were used for further investigations. The ethanolic extract of Passiflora incarnata (EEPI) was filtered and solvent distilled off. The extracts were concentrated and were subjected to phytochemical analysis.

Extraction
The powdered leaves (600 g) were extracted with ethanol at room temperature. The extract was evaporated to dryness using a distillation set-up.

Preliminary phytochemical screening
EEPI was subjected to phytochemical screening test and the analysis of the extract disclosed the presence of alkaloids, carbohydrates, phytosterols, fixed oils and fats, phenolic compounds, tannins, flavonoids, proteins, amino acids, saponins, gums, mucilage and volatile oils in ethanolic extract of Passiflora incarnata L (2).

Cells
Ehrlich Ascites Carcinoma (EAC) cells were acquired through the courtesy of Jiva Janthu Pariksha Kendra, Central animal facility at SASTRA University. They were maintained by intraperitoneal inoculation of 1×10⁶ cells/mouse. Ehrlich ascites carcinoma is one of the commonest tumours. EAC is referred to as an undifferentiated carcinoma and is originally hyper - diploid, has high transplantable capability, no-regression, rapid proliferation, shorter life span, 100% malignancy and also does not have tumor-specific transplantation antigen. EAC resembles human tumors which are the most sensitive to chemotherapy due to the fact that they are undifferentiated and that they have a rapid growth rate.

Maintenance of cells
Ehrlich ascites carcinoma cells were maintained by the courtesy of central animal facility, SASTRA University and were maintained by weekly intraperitoneal inoculation of 1×10⁶ cells/mouse (3).

Short term cytotoxicity assay
Short term in-vitro cytotoxicity was assessed using EAC cell lines by incubating the different concentration of drugs at 37°C for 3 hours. The tumor cells were aspirated from peritoneal cavity of tumour bearing mice using a 10 ml syringe and transferred to a test tube containing isotonic saline. The cells were then washed in normal saline and cell number was determined using a haemocytometer and adjusted to 1×10⁶ cells/ml. For the cytotoxicity assay, different concentrations of drug (200-1000μg/ml) were added to each and the final volume was adjusted to one ml with Phosphate buffer saline (PBS). Control tubes were kept with the solvent and without the solvent along with tumor cells. All the tubes were incubated at 37°C for 3 hours. After incubation, 0.1ml of 1% trypan blue dye in isotonic saline was added to each tube and the number of viable (unstained) and dead (stained) cells were counted using haemocytometer (4). The percent cytotoxicity (% dead cells) was calculated using the formula:

\[ \% \text{Dead cells} = \frac{\text{Total cells counted} - \text{Total viable cells}}{\text{Total cells counted}} \times 100 \]

GCMS analysis
Perkin Elmer Clarus 500 GCMS instrument was used for analyzing the compounds present in plant extract under study. Capillary column made of Elite 5ms (5% phenyl 95% dimethyl polysiloxane) of 30m length was used. The oven program was fixed to 50°C @ 8°C/min to 220°C (1min), @ 7° C/min to 280°C (10min) and injector temperature was 290°C. The carrier gas used was Helium at the flow rate of 1ml/min and the sample was injected (5) and the compounds obtained were matched using the library NIST 2005.
In silico analysis

To support the anticancer activity, the in silico approaches has been implemented in which the docking software Hex 6.3 was used. The target molecule (6) was chosen to be Bcl-2 as it is a major gene that codes for a large family of apoptosis regulating proteins (7). Compounds obtained from GCMS were docked with Bcl-2 and the results were found to be significant.

RESULTS

The percentage of dead cells was found to increase with increase in concentration of the EEPI against the EAC cell lines as shown in the Table 1 which proves that the plant extract has the capability to kill the cancer cells.

Table 1: Trypan blue assay Cytotoxicity effect of ethanolic extract of *Passiflora incarnata* L against EAC cell lines.

<table>
<thead>
<tr>
<th>Concentration of the drug(µg/ml)</th>
<th>No. of viable cells</th>
<th>No. of Dead cells</th>
<th>% viability of the cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>36</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>400</td>
<td>32</td>
<td>1</td>
<td>96.96</td>
</tr>
<tr>
<td>600</td>
<td>30</td>
<td>3</td>
<td>90.9</td>
</tr>
<tr>
<td>800</td>
<td>6</td>
<td>18</td>
<td>25</td>
</tr>
<tr>
<td>1000</td>
<td>0</td>
<td>23</td>
<td>0</td>
</tr>
</tbody>
</table>

In vitro cytotoxicity studies employing trypan blue assay was carried out to assess the cytotoxic potential of the plant extract (EEPI). The principle is based on the fact that the live cells with rigid cell membrane would not uptake the trypan blue dye whereas the dead cells with disrupted cell membrane would uptake trypan blue. When different concentrations of EEPI were assayed, the dead cells were found to increase with increase in concentration of the extracts. The dead cells of EEPI against EAC the number of dead cells at 1000µg/ml observed to be 100% (Table 1) which proves that the cancer cells were totally destroyed by the EEPI.

DISCUSSION

Cancer being the second fatal disease in India, The United States and The Western World. There is anomalous number of plant derived anticancer drugs of diverse structural types both in present clinical use and as malignant drug undergoing clinical trials. This suggests that plants will continue to be an imperative and prized resource for anticancer drug discovery. Herbal treatment proves its efficacy in medicinal field without producing any serious side effects as synthetic medicines do; hence it’s preferred to be more beneficial. Plant extracts has the ability of activating the apoptotic pathway of cancer cells and doesn’t have any ethical issues when it is used as drug formulations as it is purely herbal.

In vitro cytotoxicity studies employing trypan blue assay was carried out to assess the cytotoxic potential of the plant extract (EEPI). The principle is based on the fact that the live cells with rigid cell membrane would not uptake the trypan blue dye whereas the dead cells with disrupted cell membrane would uptake trypan blue. When different concentrations of EEPI were assayed, the dead cells were found to increase with increase in concentration of the extracts. The dead cells of EEPI against EAC the number of dead cells at 1000µg/ml observed to be 100% (Table 1) which proves that the cancer cells were totally destroyed by the EEPI.

To support the antitumor activity, the in silico analysis was done by means of docking study using the ligands identified with GC-MS analysis. The structures given by GCMS analysis were imported to Hexlog server and constructed to 3D structure which was docked with Bcl-2 which showed the interaction between the compounds and Bcl-2. Among all the compounds Phenol, 2,4-bis(1,1-dimethylethyl) was found to be the best candidate that was bound to Bcl-2 by means of hydrophobic interaction with energy level as -2.709588e+02eV.
Table 2: The binding energy and no. of hydrogen bonds interacted with the ligand.

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Structure</th>
<th>Ligand’s Name</th>
<th>Energy (in eV)</th>
<th>No. of Hydrogen Bonds</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>(3E,5E,7E)-6-Methyl-8-(2,6,6-trimethyl-1-cyclohexenyl)-3,5,7-octatrien-2-one</td>
<td>-1.529424 e+02</td>
<td>18</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>4H-1-Benzopyran-4-one,5,7-dihydroxy-2-{4-hydroxyphenyl}-</td>
<td>-2.456945 e+02</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>6Hepten-2-one,7-phenyl-</td>
<td>-2.262737 e+02</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>Bicyclo[2.2.1]heptane,1,3,3-trimethyl-</td>
<td>-2.177857 e+02</td>
<td>18</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>Cyclohexanol,1methyl-acetate</td>
<td>-2.105562 e+02</td>
<td>16</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>D-allose</td>
<td>-2.595229 e+02</td>
<td>12</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>Phenol,2,4-bis(1,1-dimethylethyl)</td>
<td>-2.709588 e+02</td>
<td>22</td>
</tr>
</tbody>
</table>
CONCLUSION

Data obtained in the present work through invitro and in silico approach depicted that the Ethanolic extract of *Passiflora incarnata* L. possess antitumor potential. After carrying out in depth pre-clinical and clinical trials, can be developed as a safe, efficacy, human compatible anticancer drug and can be useful in combating this second killing disease.

ACKNOWLEDGEMENT

The authors wish to acknowledge CARISM, SASTRA University for infrastructural support. We are grateful to Mr. David, Assistant Professor, CARISM, SASTRA University and Dr. Arunachalam, Assistant Professor, SCBT, SASTRA University for their immense support.

REFERENCES